Prospective Study

Scoring systems for peptic ulcer bleeding: Which one to use?

Ivan Budimir, Sanja Stojasavljević, Neven Baršić, Alen Bišćanin, Gorana Mirošević, Sven Bohnec, Lora Stanka Kirigin, Tajana Pavić, Neven Ljubičić

Ivan Budimir, Sanja Stojasavljević, Neven Baršić, Alen Bišćanin, Tajana Pavić, Neven Ljubičić, Division of Gastroenterology, Department of Internal Medicine, “Sestre Milosrdnice” University Hospital Center, Zagreb 10000, Croatia

Gorana Mirošević, Lora Stanka Kirigin, Division of Endocrinology, Department of Internal Medicine, “Sestre Milosrdnice” University Hospital Center, Medical and Dental Faculty, University of Zagreb, Zagreb 10000, Croatia

Sven Bohnec, Gastronterologie, Allgemeine Innere Medizin und Geriatrie, Rems-Murr Klinik Winnenden, 71364 Winnenden, Germany

ORCID number: Ivan Budimir (0000-0003-4198-8329); Sanja Stojasavljević (0000-0002-1626-3003); Neven Baršić (0000-0002-4416-4520); Alen Bišćanin (0000-0003-2923-4110); Gorana Mirošević (0000-0002-9922-2687); Sven Bohnec (0000-0002-3381-3783); Lora Stanka Kirigin (0000-0001-5003-7627); Tajana Pavić (0000-0002-0370-5001); Neven Ljubičić (0000-0002-5207-4357).

Author contributions: Budimir I, Stojasavljević S and Baršić N contributed equally to this work; Budimir I and Ljubičić N designed the research; Budimir I, Stojasavljević S, Baršić N, Bišćanin A and Pavić T performed the research; Budimir I, Stojasavljević S, Baršić N, Mirošević G, Bohnec S, Kirigin LS and Pavić T analyzed the data; Budimir I, Stojasavljević S and Baršić N wrote the paper.

Institutional review board statement: The study was reviewed and approved by the Ethics Board of the Clinical Hospital Center “Sestre Milosrdnice”, Vinogradska cesta 29, Zagreb.

Clinical trial registration statement: The study was registered in the Clinical Hospital Center “Sestre Milosrdnice” clinical trials register.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: None declared.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Sanja Stojasavljević, MD, Division of Gastroenterology, Department of Internal Medicine, “Sestre Milosrdnice” University Hospital Center, Vinogradska ul. 29, Zagreb 10000, Croatia. sanja.stojasavljevic@kbsm.hr

Telephone: +385-1-3787178
Fax: +385-1-3787448

Received: July 26, 2017
Peer-review started: July 26, 2017
First decision: August 10, 2017
Revised: August 24, 2017
Accepted: September 13, 2017
Article in press: September 13, 2017
Published online: November 7, 2017

Abstract

AIM
To compare the Glasgow-Blatchford score (GBS), Rockall score (RS) and Baylor bleeding score (BBS) in predicting clinical outcomes and need for interventions in patients with bleeding peptic ulcers.

METHODS
Between January 2008 and December 2013, 1012
consecutive patients admitted with peptic ulcer bleeding (PUB) were prospectively followed. The pre-endoscopic RS, BBS and GBS, as well as the post-endoscopic diagnostic scores (RS and BBS) were calculated for all patients according to their urgent upper endoscopy findings. Area under the receiver-operating characteristics (AUROC) curves were calculated for the prediction of lethal outcome, rebleeding, needs for blood transfusion and/or surgical intervention, and the optimal cutoff values were evaluated.

RESULTS

PUB accounted for 41.9% of all upper gastrointestinal tract bleeding, 5.2% patients died and 5.4% patients underwent surgery. By comparing the AUROC curves of the aforementioned pre-endoscopic scores, the RS best predicted lethal outcome (AUROC 0.82 vs 0.67 vs 0.63, respectively), but the GBS best predicted need for hospital-based intervention or 30-d mortality (AUROC 0.84 vs 0.57 vs 0.64), rebleeding (AUROC 0.75 vs 0.61 vs 0.53), need for blood transfusion (AUROC 0.83 vs 0.63 vs 0.58) and surgical intervention (0.82 vs 0.63 vs 0.52) The post-endoscopic RS was also better than the post-endoscopic BBS in predicting lethal outcome (AUROC 0.82 vs 0.69, respectively).

CONCLUSION

The RS is the best predictor of mortality and the GBS is the best predictor of rebleeding, need for blood transfusion and/or surgical intervention in patients with PUB. There is no one ‘perfect score’ and we suggest that these two tests be used concomitantly.

Key words: Upper gastrointestinal bleeding; Peptic ulcer bleeding; Glasgow-Blatchford score; Rockall score; Baylor bleeding score

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Endoscopic hemostasis represents the cornerstone of upper gastrointestinal bleeding treatment, and several scores have been developed for the prediction of rebleeding. This is a first study on Croatian patients to include over 1000 participants with peptic ulcer bleeding, and the aim was to compare three scores (Glasgow Blatchford score, Rockall score and Baylor bleeding score) in the prediction of peptic ulcer bleeding treatment outcome, including need for hospital-based intervention or 30-d mortality, 30-d rebleeding rate, 30-d mortality rate, and needs for surgical intervention and blood transfusion, and to find optimal cutoff values that indicate high-risk patients.

Budimir I, Stojasavljević S, Baršić N, Bišćanin A, Mirošević G, Bohnec S, Kirigin LS, Pavić T, Ljubičić N. Scoring systems for peptic ulcer bleeding: Which one to use? World J Gastroenterol 2017; 23(41): 7450-7458 Available from: URL: http://www.

wjgnet.com/1007-9327/full/v23/i41/7450.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i41.7450

INTRODUCTION

Upper gastrointestinal bleeding (UGIB) is a common medical emergency. Incidence rates of UGIB demonstrate variations ranging from 48 to 160 cases per 100000 population[1]. The most common causes of acute UGIB are non-vascular, where 28% to 59% are caused by peptic ulcer bleeding (PUB)[1-3]. Endoscopic hemostasis represents the cornerstone of UGIB treatment, and several scores have been developed for the prediction of clinical intervention (i.e. Rockall score (RS), Glasgow-Blatchford score (GBS), Baylor bleeding score (BBS), Cedars-Sinai Medical Center predictive index, Almea score, AIMS65 score)[4-14]. The recently published American College of Gastroenterology practice guidelines on the management of patients with ulcer bleeding recommend risk assessment in all patients in order to stratify them into high or low risk categories, since it may assist in initial decisions regarding the timing of endoscopy, time of discharge, and level of care[15].

The GBS is a pre-endoscopic score and contains the following parameters: initial hemoglobin levels, urea, blood pressure, pulse, known syncope, melena, and liver or cardiac failure. Each variable has an appointed numeric value and the maximal number of points is 23 (Table 1). The GBS was designed to predict lower risk bleeds, and a GBS value of 1 or lower indicates very low risk category[8,9]. The most commonly used RS consists of a pre-endoscopic evaluation part, which includes age, signs of shock and comorbidities, along with an endoscopic part, which evaluates high-risk endoscopic characteristics as well (known as the pre-endoscopic RS) (Table 2). Each variable is appointed a numeric value and every value > 2 indicates a high-risk patient[71]. The maximal pre-endoscopic RS value is 7, and the maximal post-endoscopic value is 11. The post-endoscopic RS can be calculated if bleeding is diagnosed and evaluated with upper endoscopy[15-17]. The BBS contains a pre-endoscopic evaluation part, which includes age, severity and duration of associated diseases, along with a post-endoscopic part, which evaluates the position and type of fresh bleeding (Table 3). The maximal pre-endoscopic BBS is 15, and the maximum total (pre-endoscopic and post-endoscopic) BBS is 24[18].

The RS was primarily developed to predict mortality and the GBS to evaluate need for clinical intervention[6-14]. Secondarily, they can be applied to assess rebleeding risk. The BBS was primarily developed to identify patients at high risk for rebleeding after endoscopic hemostasis[9,16]. In previous studies,
the GBS has been shown to be better than the pre-endoscopic and post-endoscopic RS in predicting the need for hospital-based intervention in patients with UGIB\(^{[6,13,19]}\). On the other hand, the RS appeared to be better at predicting mortality after rebleeding, contributing to more accurate diagnostics and shorter hospital stays\(^{[7,13,14]}\). Recent studies have shown that early endoscopy (within 24 h of presentation) is performed in only half of patients with UGIB, demonstrating the need for reliable and accurate pre-endoscopic risk assessment.

This is the first prospective study in Croatia to include over 1000 patients with PUB, and the aim was to compare the GBS, pre-endoscopic RS and pre-endoscopic BBS, as well as the post-endoscopic RS and post-endoscopic BBS, in the prediction of PUB treatment outcome, need for hospital-based intervention (endoscopic treatment, transfusion, surgery intervention) or 30-d mortality, including 30-d rebleeding rate, 30-d mortality rate, and needs for surgical intervention and blood transfusion, and to find optimal cutoff values that indicate high-risk patients.

### MATERIALS AND METHODS

This prospective study was conducted in the University Hospital Center “Sestre Milosrdnice” that covers a population of approximately 300,000 in the City of Zagreb, Croatia. All patients presenting to the Emergency Unit between January 2008 and December 2013 with hematemesis, melena, hematochezia, or blood admixture upon nasogastric insertion were considered for study enrolment. If initial work-up indicated the need for hospitalization, patients were admitted to the Interventional Gastroenterology Unit.

Upper gastrointestinal endoscopy was performed in all patients within 24 h of admission. Only patients with gastric and/or duodenal ulcers, or an ulcer at the site of gastro-enteric anastomosis found during emergency endoscopy, without any other possible cause of bleeding were included in the study. All patients with high-risk ulcer stigmata and patients selected depending on clinical judgment received high-dose acid suppression therapy (pantoprazole oresomeprazole 80 mg as an intravenous bolus, followed by 40 mg intravenously 2 times daily or 200 mg daily in the form of continuous infusion for at least 48 h followed by 40 mg daily by mouth). The institution’s ethics committee approved the study. Data was prospectively entered into a database, with patient details stored in a depersonalized manner to protect patient confidentiality.

### Data collection

The following data were collected for each patient: demographic data, history of ulcer or liver disease, coexisting and past illnesses, medication use, clinical characteristics of the bleeding episode, laboratory results, endoscopic diagnosis including stigmata of ongoing or recent hemorrhage, endoscopic treatment, rebleeding, surgical therapy, duration of hospitalization and cause of death. The grading of overall health and co-morbidity was performed according to the American Society of Anesthesiology (ASA) classification (grade 1, normal healthy patients; grade 2, mild systemic illness; grade 3, severe but incapacitating systemic illness; grade 4, life-threatening illness). Stigmata of hemorrhage were defined according to the Forrest classification (Forrest Ia, spurting bleeding; Forrest Ib, oozing bleeding; Forrest IIa, non-bleeding visible vessel; Forrest IIb, adherent clot; Forrest IIc, hemat in ulcer base; Forrest III, clean ulcer base).

Shock was defined as syncope or signs of shock at physical examination, including systolic blood pressure less than 100 mmHg and pulse rate more than 100 beats/min.

Post-hemorrhagic anemia was corrected with red blood cell transfusion (2 units, approximately 500 mL) at a hemoglobin threshold of 70-80 g/L.

All patients diagnosed with PUB and high-risk stigmata underwent initial hemostasis (injection of dilute epinephrine into and around the bleeding point, positioning of clips or thermal coagulation, or both, but never epinephrine alone). Two biopsy specimens were obtained from the gastric antrum and body in all patients and the presence of Helicobacter pylori (H. pylori) infection was assessed by histopathological examination of the specimens using hematoxylin-eosin (HE) stain.

All patients with negative histology for H. pylori at index endoscopy had a control endoscopy with repeating biopsy samples, or urea breath test (UBT), performed 2 wk after proton-pump inhibitor treatment was discontinued. Patients in whom the described protocol was not followed were excluded from the study about H. pylori infection.

### Table 1 Glasgow-Blatchford score

| Blood urea, mmol/L | Assigned score |
|-------------------|----------------|
| 10.0-24.9         | 4              |
| ≥ 25              | 6              |
| Hemoglobin for men, g/dl |   |
| 12-12.9           | 1              |
| 10-11.9           | 3              |
| < 10              | 6              |
| Hemoglobin for women, g/dl |   |
| 10-11.9           | 1              |
| < 10              | 6              |
| Systolic blood pressure, mmHg |   |
| 100-109           | 1              |
| 90-99             | 2              |
| < 90              | 3              |
| Other markers     |                |
| Pulse ≥ 100       | 1              |
| Melena            | 1              |
| Syncope           | 2              |
| Hepatic disease   | 2              |
| Cardiac failure   | 2              |

The above table provides the assigned score for each Blood urea, Hemoglobin, and Systolic blood pressure for each patient. The table also includes other markers such as Pulse, Melena, Syncope, Hepatic disease, and Cardiac failure. The data collection was performed according to the American Society of Anesthesiology (ASA) classification.
of variance test were used to analyze differences in quantitative data. The discriminative ability of the scoring systems to predict outcomes was evaluated by receiver operating characteristics curves (ROC) with 95%CI. The areas under ROC (AUROC) curves were compared using the method of Delong et al.\cite{26} for the calculation of the standard error of the Area Under the Curve (AUC) and of the difference between two AUCs. The optimal thresholds of the GBS, RS and BBS for the prediction of rebleeding, death, and needs for blood transfusion and/or surgical intervention were identified as the threshold associated with the highest Youden index\cite{27}. A two-tailed significance level of 5% was used in all comparisons. All analyses were performed using a statistical package MedCalc for Windows, version 15.8 (MedCalc Software, Ostend, Belgium).

**RESULTS**

The analysis included 2643 patients with UGIB, of that 2326 (88%) patients had non-variceal bleeding, 225 (8.5%) had variceal bleeding, and 92 (3.5%) had an unidentified cause of bleeding.

For all patients with gastric ulcer in whom recurrent bleeding was not observed, control endoscopy was performed 4-5 d after initial hemostasis and biopsy specimens were obtained from the margins and base of gastric ulcers to exclude malignancy. Control endoscopy with histology had been planned to be performed in all patients with gastric ulcer.

**Table 2 Rockall score**

| Variable                  | Pre-endoscopic score | Points |
|---------------------------|----------------------|--------|
| Age, yr                   | < 60                 | 0      |
| Systolic blood pressure   | 60-79                | 1      |
| ≥ 80                      | 2                    |        |
| Shock                     | Systolic blood pressure ≥ 100 | 3 |
| Pulse ≥ 100/min           | No major comorbidity | 4      |
| Comorbidity               | Heart failure, ischemic heart disease, any major comorbidity | 5      |
| Renal failure, liver failure, disseminated malignancy | 6      |

**Table 3 Baylor bleeding score**

| Assigned score | Age, yr | No. of parallel illnesses | Severity of illnesses | Site of bleeding | Stigmata of bleeding |
|----------------|---------|---------------------------|-----------------------|-----------------|----------------------|
| 0              | < 30    | 0                         |                       |                 | Clot                 |
| 1              | 30-49   | 1 or 2                    |                       |                 | Visible vessel       |
| 2              | 50-59   | 3                         | Chronic               | Posterior wall bulb |                      |
| 3              | 60-69   | 4                         | Acute                 |                 |                      |
| 4              | ≥ 70    | 5                         | Active bleeding       |                 |                      |
| 5              |         |                           | Pre-endoscopic        |                 | Post-endoscopic      |

Rebleeding was defined as one or more signs of recurrent bleeding, including fresh hematemesis or melena, hematochezia, aspiration of fresh blood via nasogastric tube, instability of vital signs, and reduction of hemoglobin levels by 2 g/dL or more, occurring 24-h after the primary bleeding was stopped.

**Table 4**

| Rebleeding | Definition |
|------------|------------|
| Rebleeding | One or more signs of recurrent bleeding, including fresh hematemesis or melena, hematochezia, aspiration of fresh blood via nasogastric tube, instability of vital signs, and reduction of hemoglobin levels by 2 g/dL or more, occurring 24-h after the primary bleeding was stopped. |

**Statistical analysis**

The Mann-Whitney U-test and Kruskal-Wallis analysis of variance test were used to analyze differences in quantitative data. The discriminative ability of the scoring systems to predict outcomes was evaluated by receiver operating characteristics curves (ROC) with 95%CI. The areas under ROC (AUROC) curves were compared using the method of Delong et al.\cite{26} (1988) for the calculation of the standard error of the Area Under the Curve (AUC) and of the difference between two AUCs. The optimal thresholds of the GBS, RS and BBS for the prediction of rebleeding, death, and needs for blood transfusion and/or surgical intervention were identified as the threshold associated with the highest Youden index\cite{27}. A two-tailed significance level of 5% was used in all comparisons. All analyses were performed using a statistical package MedCalc for Windows, version 15.8 (MedCalc Software, Ostend, Belgium).
Budimir I et al. Scoring systems for peptic ulcer bleeding

Table 4 Patient characteristics and clinical outcomes

| Age                          | Median, yr | 65.3 (20-100) |
|------------------------------|------------|---------------|
| Sex                          | Male/Female| 638 (63)/374 (37) |
| Findings at endoscopy        |            |               |
| Gastric ulcers               | 496 (49)   |               |
| Duodenal ulcers              | 476 (47)   |               |
| Gastric and duodenal ulcers  | 24 (2.4)   |               |
| Ulcer on gastro-enteric anastomosis | 16 (1.6) |               |
| High-risk ulcers (Forrest I a-II b) | 526 (52) |               |
| Forrest I a                  | 61 (6)     |               |
| Forrest I b                  | 111 (11)   |               |
| Forrest II a                 | 212 (21)   |               |
| Forrest II b                 | 142 (14)   |               |
| Low- risk ulcers (Forrest II c-III) | 486 (48) |               |
| Forrest II c                 | 172 (17)   |               |
| Forrest III                  | 314 (31)   |               |
| Hemodynamic shock            | 111 (11)   |               |
| Comorbidity                  |            |               |
| Ischemic and valvular heart disease | 213 (21.5) |               |
| Liver disease                | 172 (17)   |               |
| Renal failure                | 111 (11)   |               |
| Any malignancy               | 131 (12.9) |               |
| Comorbidity (ASA class)      |            |               |
| ASA I                        | 142 (14)   |               |
| ASA II                       | 283 (28)   |               |
| ASA III-IV                   | 587 (58)   |               |
| H. pylori                    | Tested     | 760 (75.1)    |
| H. pylori-positive           | 324 (42.6) |               |
| Drugs                        |            |               |
| Without previous therapy     | 433 (42.8) |               |
| NSAIDs                       | 284 (28.1) |               |
| Acetylsalicylic acid         | 203 (20)   |               |
| Antiplatelet therapy         | 31 (3.1)   |               |
| Anticoagulant therapy        | 41 (4)     |               |
| NOAC                         | 2 (2)      |               |
| Treatment                    |            |               |
| Endoscopic therapy           | 587 (58)   |               |
| Epinephrine                  | 213 (36.3) |               |
| Hemoclips                    | 156 (26.6) |               |
| Hemoclips + epinephrine      | 180 (30.7) |               |
| Thromcoagulation             | 26 (4.4)   |               |
| Thromcoagulation + epinephrine| 12 (2)   |               |
| Repeated endoscopic therapy  | 71 (7)     |               |
| Blood transfusion required   | 496 (49)   |               |
| Red blood cell               | 406 (40.1) |               |
| Median (range), unit         | 2.5 (1-16) |               |
| Fresh frozen plasma          | 81 (8)     |               |
| Median (range), unit         | 2 (1-6)    |               |
| Platelet                     | 9 (0.9)    |               |
| Median (range), unit         | 6 (4-8)    |               |
| Whole blood                  | 0 (0)      |               |
| Surgery                      | 55 (5.4)   |               |
| Outcome                      |            |               |
| Rebleeding                   | 95 (9.4)   |               |
| Rebleeding (anticoag, and NOAC) | 9 (14.8)  |               |
| 30-d mortality               | 53 (5.2)   |               |
| Median hospital stay, d      | 6 (0-45)   |               |

Data are presented as n (%) or mean (range). ASA: American society of anesthesiology; NOAC: New(er) oral anticoagulant; NSAIDs: Non-steroidal anti-inflammatory drugs.

patients with ulcer bleeding, and in 57.3% hemostasis was achieved with hemoclips or with combination hemoclips/diluted epinephrine. The rate of rebleeding was 9.4%, and in patients that were on anticoagulant therapy the rebleeding rate was 14.8% (P = 0.245), which was not statistically significant. In total, 5.4% of the patients were transferred to the Department of Surgery. The 30-d mortality was 5.2% and the median length of hospitalization was 6 d. Transfusion of red blood cells was performed in 49% of patients. Patients were predominantly men (median age 65.3). In 52% of patients, high-risk ulcers were verified (Forrest Ia-II b), 11% of the patients presented with shock, and moderate to severe comorbidity was found in 58%. Furthermore, 28.1% patients with peptic ulcer had been taking nonsteroidal anti-inflammatory drugs, 20% acetylsalicylic acid, 3.1% antiplatelet medication and 6% anticoagulant therapy. H. pylori testing was performed in 760 (75.1%) patients, of which 324 (42.6%) tested positive. Table 4 shows the patient characteristics and clinical outcomes.

Using ROC curve analysis we found that the GBS was clearly superior to pre-endoscopic RS and pre-endoscopic BBS, in predicting need for hospital-based intervention or 30-d mortality (AUROC 0.83 (95%CI: 0.81-0.86) vs [0.63 (95%CI: 0.59-0.68)] vs [0.57 (95%CI: 0.53-0.61)]). GBS: Glasgow-Blatchford score; BBS: Baylor bleeding score; RS: Rockall score.

The cutoff value that maximized the sum of the sensitivity and specificity for predicting 30-d mortality for the pre-endoscopic RS was 4 (sensitivity 0.63, specificity 0.85, total 1.48), and 5 for the post-endoscopic RS (sensitivity 0.83, specificity 0.68, total 1.51). Based on ROC analysis of sensitivity and specificity, the optimal cutoff value of the pre-endoscopic BBS for 30-d mortality was 8 (0.63 sensitivity, 0.58 specificity, total 1.21), and the optimal cutoff post-endoscopic BBS value for 30-d mortality was 9 (0.88 sensitivity, 0.40 specificity, total 1.28).

When assessing scores for the prediction of lethal outcome in patients with PUB, the pre-endoscopic...
RS was superior compared to the GBS and the pre-endoscopic BBS (AUROC 0.82 vs 0.67 vs 0.63, respectively) (Figure 2A).

Based on the ROC analysis of sensitivity and specificity, the optimal cutoff GBS value for 30-d mortality was 12 (0.49 sensitivity, 0.75 specificity, total 1.24), for rebleeding 11 (0.71 sensitivity, 0.67 specificity, total 1.38), for blood transfusion 9 (0.71 sensitivity, 0.67 specificity, total 1.38) and for surgery 12 (0.71 sensitivity, 0.76 specificity, total 1.47).

The GBS score was superior to the pre-endoscopic RS and BBS in the prediction of rebleeding (AUROC 0.75 vs 0.61 vs 0.52) (Figure 2B).

The GBS score was superior to the pre-endoscopic RS and BBS in predicting the need for blood transfusion (AUROC 0.83 vs 0.63 vs 0.59, respectively) (Figure 2C) and transfer to the Department of Surgery (AUROC 0.82 vs 0.63 vs 0.52, respectively) (Figure 2D). Also, the post-endoscopic RS was superior to the post-endoscopic BBS (AUROC 0.82 vs 0.69) in the prediction of lethal outcome (Figure 3A).

There was no significant difference between the post-endoscopic RS and BBS in the prediction of rebleeding (AUROC 0.70 vs 0.73) (Figure 3B).

The rebleeding cutoff point that maximized the sum of the sensitivity and specificity for the pre-endoscopic BBS was 3 (sensitivity 0.90, specificity 0.19, total 1.09), and 11 for the post-endoscopic BBS (sensitivity 0.66, specificity 0.76, total 1.42).

There was no significant difference between the post-endoscopic RS and BBS in predicting the need for blood transfusion (AUROC 0.68 vs 0.71) (Figure 3C) and transfer to the Department of Surgery (AUROC 0.68 vs 0.74) (Figure 3D).

**DISCUSSION**

UGIB is the most important cause of emergency gastroenterological admissions and the most frequent condition requiring emergency endoscopy[23]. The most common causes of acute UGIB are non-variceal, of which 30% to 60% are attributed to PUB[28]. In our study, 42% of all non-variceal bleeding was caused by PUB. In order to assess the adequate timing of
endoscopy and selection of patients for hospital admission, several scoring systems for risk estimation have been developed. With the array of available scoring systems, it is often difficult to select the ideal scoring system for a particular patient or clinical outcome of interest. Therefore, in this study, we compared the performance of these scoring systems in the risk assessment of various clinical outcomes.

Our study showed that the GBS is superior to the pre-endoscopic RS and BBS in predicting need for hospital-based intervention or 30-d mortality. This is in concordance with the results from a study by Laursen et al\(^6\). Similar data was published by Italian and Dutch researchers, who also found low values under the ROC curve ([0.59-0.68] and 0.61) and concluded that the RS is not appropriate for prediction of rebleeding\(^{16,30}\).

Our study showed that the GBS is superior to the pre-endoscopic RS and pre-endoscopic BBS in predicting the needs for blood transfusion and/or transfer to the Department of Surgery. Our study showed that the GBS is superior to the GBS score.

Our study showed that there is no significant difference between the post-endoscopic BBS and post-endoscopic RS in predicting peptic ulcer rebleeding. This is in concordance with the results from a study by Laursen et al\(^6\). Similar data was published by Italian and Dutch researchers, who also found low values under the ROC curve ([0.59-0.68] and 0.61) and concluded that the RS is not appropriate for prediction of rebleeding\(^{16,30}\).

Our study showed that the GBS is superior to the pre-endoscopic RS and pre-endoscopic BBS in predicting the needs for blood transfusion and/or transfer to the Department of Surgery. The ROC curve for GBS rebleeding was similar to the GBS ROC curve for blood transfusion requirement and transfer to the Department of Surgery because peptic ulcer rebleeding is the main cause of blood transfusion requirement and need for surgical intervention. Bryant et al\(^{19}\) published similar data.

Our study showed that the pre-endoscopic RS was superior to the GBS and pre-endoscopic BBS

Figure 3  Comparison of the post-endoscopic Rockall score and post-endoscopic Baylor bleeding score for the prediction of death recurrent bleeding, transfusion or surgical intervention. AUROC: [0.82 (95%CI: 0.79-0.84)] vs [0.69 (95%CI: 0.65-0.72)]; B: AUROC [0.70 (95%CI: 0.67-0.73)] vs [0.73 (95%CI: 0.70-0.76)]; C: AUROC [0.66 (95%CI: 0.62-0.70)] vs [0.65 (95%CI: 0.61-0.69)]; D: AUROC [0.68 (95%CI: 0.65-0.71)] vs [0.74 (95%CI: 0.71-0.77)]. BBS: Baylor bleeding score; RS: Rockall score.
in predicting mortality. The RS best predicted fatal outcome because it incorporated the majority of risk factors (age, shock, moderate to severe co-morbidities and high-risk endoscopic signs for rebleeding), which was valuable in a multivariable analysis of risk for fatal outcome. Our study showed that the post-endoscopic RS is superior to the post-endoscopic BBS in predicting lethal outcome in patients with PUB. Laursen did not find any significant difference in AUROC among post-endoscopic BBS and post-endoscopic RS.

According to studies by Hyett et al. and Bryant et al., the GBS cutoff points for high-risk of lethal outcome and rebleeding were ≥ 10 and ≥ 12, respectively. In a recent retrospective study, Lim et al. suggested urgent endoscopy in the first 13 h after clinical presentation in high-risk patients with GBS > 12, in the first 24 h in patients with GBS > 7 and for patients with GBS values between 4 and 7 urgent endoscopy in the first 24 h is recommended, but not necessary.

Our cutoff points for high-risk of rebleeding and lethal outcome in PUB patients are significantly different in comparison with original research papers (GBS ≥ 2, pre-endoscopic BBS > 5, post-endoscopic BBS ≥ 10, post-endoscopic RS ≥ 4), which all refer to UGIB. An explanation for this could be that the original series included an unselected group of patients with UGIB, with a significant proportion of patients with a low-risk of death, recurrent bleeding, and needs for blood transfusion and/or surgical intervention. These were patients that presented with low-risk bleeding ulcers (Forrest Ic and Forrest III), Mallory-Weiss syndrome, ulcerative esophagitis, angiodysplasia and portal hypertensive gastropathy.

When considering possible limitations of our study, there is always a certain level of subjectivity in the endoscopic classification of ulcers and variation in endoscopic treatment. Furthermore, our study had a relatively short follow-up period of 30 d.

By comparing the ROC curves of the aforementioned pre-endoscopic scores, the RS proved to be the best score for predicting lethal outcome. The post-endoscopic RS was also better than the post-endoscopic BBS in predicting lethal outcome in patients with PUB. On the other hand, among the three pre-endoscopic scores, the GBS best predicted need for hospital-based intervention or 30-d mortality, rebleeding, and needs for blood transfusion and/or surgical intervention.

REFERENCES

1 Holster H, Kuipers EJ. Management of acute nonvariceal upper gastrointestinal bleeding: current policies and future perspectives. World J Gastroenterol 2012; 18: 1202-1207 [PMID: 22468083 DOI: 10.3748/wjg.v18.i11.1202]
2 Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335 [PMID: 21490373 DOI: 10.1136/ gut.2010.228437]
3 Bardou M, Benhaberou-Brun D, Le Ray I, Barkun AN. Diagnosis and management of nonvariceal upper gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol 2012; 9: 97-104 [PMID: 22230903 DOI: 10.1038/nrgastro.2011.260]
4 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2010; 105: 1430-1437 [PMID: 20923022 DOI: 10.1038/ajg.2010.480]
5 Grañmek IM, Dumonceau JM, Kuipers EJ, Anker-Sand, DS, Kurien M, Rottando G, Hulc T, Diniz-Ribeiro M, Marmo R, Racz I, Arezzo A, Hoffmann RT, Lesur G, de Franchis R, Aufakken L, Veitch A, Radaelli F, Salgueiro P, Cardoso R, Maia L, Zullo A, Cipolletta L, Hassan C. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-46 [PMID: 26417980 DOI: 10.1055/s-0034-1393172]
6 Laursen SB, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patient with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012; 10: 1130-1135 [PMID: 22801061 DOI: 10.1016/j.cgh.2012.06.022]
7 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-321 [PMID: 8675081]
8 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. Lancet 2000; 356: 1318-1321 [PMID: 11073021 DOI: 10.1016/S0140-6736(00)02816-6]
9 Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997; 315: 510-514 [PMID: 9329304]
10 Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2: 394-397 [PMID: 4136718]
11 Budimir I, Gradišer M, Nikolić M, Baršić N, Ljubičić N, Krkalj D, Budimir IJ. Glasgow Blatchford, pre-endoscopic Rockall and AIMS65 scores show no difference in predicting rebleeding rate and mortality in variceal bleeding. Scand J Gastroenterol 2016; 51: 1375-1379 [PMID: 27356670 DOI: 10.1080/00365521.2016.1200138]
endoscopic risk stratification in patients with acute upper-gastrointestinal haemorrhage. Eur J Gastroenterol Hepatol 2002; 14: 497-501 [PMID: 11984147]

Laursen SB. Treatment and prognosis in peptic ulcer bleeding. Dan Med J 2014; 61: B4797 [PMID: 24547604]

Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: a results of a nationwide audit. Gut 2010; 59: 1022-1029 [PMID: 20357318 DOI: 10.1136/gut.2008.174599]

Maggio D, Barkun AN, Martel M, Elouali S, Gralnek IM; Reason Investigators. Predictors of early rebleeding after endoscopic therapy in patients with nonvariceal upper gastrointestinal bleeding secondary to high-risk lesions. Can J Gastroenterol 2013; 27: 454-458 [PMID: 23963874]

Imperiale TF, Dominitz JA, Provenzale DT, Boes LP, Rose CM, Bowers JC, Musick BS, Azzouz F, Perkins SM. Predicting poor outcomes from upper gastrointestinal hemorrhage. Arch Intern Med 2007; 167: 1291-1296 [PMID: 17592103 DOI: 10.1001/archinte.167.12.1291]

DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845 [PMID: 3203132]

Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-35 [PMID: 15405679]

van Leeuwen ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008; 22: 209-224 [PMID: 18346679 DOI: 10.1016/j.bpcg.2007.10.011]

Oldé Damink SW, Dejong CH, Deutz NE, van Berlo CL, Soeters PB. Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. Med Hypotheses 1999; 52: 515-519 [PMID: 10459831 DOI: 10.1054/mehy.1998.0026]

Camellini L, Merighi A, Pagnini C, Azzolin F, Guazzetti S, Scarcelli A, Manenti F, Rigo GP. Comparison of three different risk scoring systems in non-variceal upper gastrointestinal bleeding. Dig Liver Dis 2004; 36: 271-277 [PMID: 15115340 DOI: 10.1016/j.dld.2003.10.017]

Kim BJ, Park MK, Kim SJ, Kim ER, Min BH, Son HJ, Rhee PL, Kim JJ, Rhee JC, Lee JH. Comparison of scoring systems for the prediction of outcomes in patients with nonvariceal upper gastrointestinal bleeding: a prospective study. Dig Dis Sci 2009; 54: 2523-2529 [PMID: 19104934 DOI: 10.1007/s10620-008-0654-7]

Lim LG, Ho KY, Chan YH, Teoh PL, Khor CJ, Lim LL, Rajnakova A, Ong TZ, Yeoh KG. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011; 43: 300-306 [PMID: 21360421 DOI: 10.1055/s-0030-1256110]
